Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, aldosterone antagonists, and device treatments have all been used in numerous major randomized controlled trials over the past few decades to show better survival in HF patients [30-32]. Therapy with mineralocorticoid receptor antagonist (MRA), angiotensin receptor-neprilysin inhibitor (ARNI), or sodium-glucose cotransporter-2 inhibitor (SGLT2i) may have potential benefits in patients with HFrEF according to post hoc and subgroup analyses of heart failure trials [27]. The gene discussed is ACE; the disease is heart failure.